Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.
This will be a placebo controlled, randomized, double-blind, comparative effectiveness study, in which we patients are enrolled during an emergency department (ED) visit for acute radicular low back pain (LBP) and followed by telephone two and seven days later. Patients will be randomized to receive an oral dose of dexamethasone for 2 consecutive days or placebo during an ED visit for acute radicular LBP. Every patient will receive a 7 day supply of ibuprofen and a low back pain education session.
Conditions:
🦠 Radiculopathy, Lumbosacral Region 🦠 Back Pain With Radiation 🦠 Low Back Pain
🗓️ Study Start (Actual) 5 July 2023
🗓️ Primary Completion (Estimated) July 2025
✅ Study Completion (Estimated) August 2025
👥 Enrollment (Estimated) 132
🔬 Study Type INTERVENTIONAL
📊 Phase PHASE4
Locations:
📍 Bronx, New York, United States
📍 Bronx, New York, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Present to ED primarily for management of acute radicular LBP, defined as pain or paresthesia originating from the lower back and radiating to the buttock and or leg in a radicular pattern. Some patients may not have prominent LBP but a radicular symptom--we will include these patients as well.
    • * Patient is to be discharged home.
    • * Age 18-70 Enrollment will be limited to adults \<70 years because of the increased risk of adverse medication effects in older adults.
    • * Pain duration \<2 week
    • * Prior to the acute attack of radicular LBP, back pain cannot occur more frequently than half of the days in the last 3 months. Patients with more frequent back pain/sciatica are at increased risk of poor pain and functional outcomes.10
    • * Non-traumatic cause of pain: no substantial and direct trauma to the back within the previous month
    • * Functionally impairing radicular LBP: A baseline score of \> 5 on the Roland-Morris Disability Questionnaire

    Exclusion Criteria:

    • * Not available for follow-up
    • * Pregnant
    • * Chronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis
    • * Allergic to or intolerant of investigational medications
    • * Chronic steroid use
    • * Contra-indications to investigational medications: 1) known peptic ulcer disease, chronic dyspepsia, or history of gastrointestinal bleed 2) Severe heart failure (NYHA 2 or worse) 3) Chronic kidney disease (GFR \<60ml/min) 4) Current use of anti-coagulants 5) cirrhosis (Child Pugh A or worse) or hepatitis (transaminases 2x the upper limit of normal)
Ages Eligible for Study: 18 Years to 70 Years (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 31 January 2023
  • First Submitted that Met QC Criteria 8 February 2023
  • First Posted 9 February 2023

Study Record Updates

  • Last Update Submitted that Met QC Criteria 14 May 2024
  • Last Update Posted 16 May 2024
  • Last Verified May 2024